273 related articles for article (PubMed ID: 14529727)
41. Intramuscular distribution of botulinum toxin--visualized by MRI.
Elwischger K; Kasprian G; Weber M; Meyerspeer M; Linder C; Auff E; Prayer D; Sycha T; Kranz G
J Neurol Sci; 2014 Sep; 344(1-2):76-9. PubMed ID: 25023196
[TBL] [Abstract][Full Text] [Related]
42. Botulinal neurotoxin C1 complex genes, clostridial neurotoxin homology and genetic transfer in Clostridium botulinum.
Hauser D; Gibert M; Marvaud JC; Eklund MW; Popoff MR
Toxicon; 1995 Apr; 33(4):515-26. PubMed ID: 7570637
[TBL] [Abstract][Full Text] [Related]
43. Translocation of botulinum neurotoxin serotype A and associated proteins across the intestinal epithelia.
Lam TI; Stanker LH; Lee K; Jin R; Cheng LW
Cell Microbiol; 2015 Aug; 17(8):1133-43. PubMed ID: 25640773
[TBL] [Abstract][Full Text] [Related]
44. Extracranial injections of botulinum neurotoxin type A inhibit intracranial meningeal nociceptors' responses to stimulation of TRPV1 and TRPA1 channels: Are we getting closer to solving this puzzle?
Zhang X; Strassman AM; Novack V; Brin MF; Burstein R
Cephalalgia; 2016 Aug; 36(9):875-86. PubMed ID: 26984967
[TBL] [Abstract][Full Text] [Related]
45. Recovery of rat muscle size but not function more than 1 year after a single botulinum toxin injection.
Ward SR; Minamoto VB; Suzuki KP; Hulst JB; Bremner SN; Lieber RL
Muscle Nerve; 2018 Mar; 57(3):435-441. PubMed ID: 28556093
[TBL] [Abstract][Full Text] [Related]
46. Isolation and Characterization of the Novel Botulinum Neurotoxin A Subtype 6.
Moritz MS; Tepp WH; Bradshaw M; Johnson EA; Pellett S
mSphere; 2018 Oct; 3(5):. PubMed ID: 30355669
[TBL] [Abstract][Full Text] [Related]
47. Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg.
Carli L; Montecucco C; Rossetto O
Muscle Nerve; 2009 Sep; 40(3):374-80. PubMed ID: 19618426
[TBL] [Abstract][Full Text] [Related]
48. Therapeutic effectiveness of botulinum neurotoxin A: potent blockade of autonomic transmission by targeted cleavage of only the pertinent SNAP-25.
Lawrence GW; Ovsepian SV; Wang J; Aoki KR; Dolly JO
Neuropharmacology; 2013 Jul; 70():287-95. PubMed ID: 23485402
[TBL] [Abstract][Full Text] [Related]
49. British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin.
Marion MH; Humberstone M; Grunewald R; Wimalaratna S
Pract Neurol; 2016 Aug; 16(4):288-95. PubMed ID: 26976927
[TBL] [Abstract][Full Text] [Related]
50. Different types of botulinum toxin in humans.
Eleopra R; Tugnoli V; Quatrale R; Rossetto O; Montecucco C
Mov Disord; 2004 Mar; 19 Suppl 8():S53-9. PubMed ID: 15027055
[TBL] [Abstract][Full Text] [Related]
51. Jitter Evaluation in Distant and Adjacent Muscles after Botulinum Neurotoxin Type A Injection in 78 Cases.
Kouyoumdjian JA; Graça CR; Oliveira FN
Toxins (Basel); 2020 Aug; 12(9):. PubMed ID: 32867187
[TBL] [Abstract][Full Text] [Related]
52. Bone and cartilage changes in rabbit mandibular condyles after 1 injection of botulinum toxin.
Matthys T; Ho Dang HA; Rafferty KL; Herring SW
Am J Orthod Dentofacial Orthop; 2015 Dec; 148(6):999-1009. PubMed ID: 26672706
[TBL] [Abstract][Full Text] [Related]
53. Combining strength training and botulinum neurotoxin intervention in children with cerebral palsy: the impact on muscle morphology and strength.
Williams SA; Elliott C; Valentine J; Gubbay A; Shipman P; Reid S
Disabil Rehabil; 2013 Apr; 35(7):596-605. PubMed ID: 22928803
[TBL] [Abstract][Full Text] [Related]
54. Enhancement of the endopeptidase activity of purified botulinum neurotoxins A and E by an isolated component of the native neurotoxin associated proteins.
Sharma SK; Singh BR
Biochemistry; 2004 Apr; 43(16):4791-8. PubMed ID: 15096048
[TBL] [Abstract][Full Text] [Related]
55. Comparison between neurectomy and botulinum toxin A injection for denervated skeletal muscle.
Tsai FC; Hsieh MS; Chou CM
J Neurotrauma; 2010 Aug; 27(8):1509-16. PubMed ID: 20528164
[TBL] [Abstract][Full Text] [Related]
56. Longer-acting and highly potent chimaeric inhibitors of excessive exocytosis created with domains from botulinum neurotoxin A and B.
Wang J; Zurawski TH; Bodeker MO; Meng J; Boddul S; Aoki KR; Dolly JO
Biochem J; 2012 May; 444(1):59-67. PubMed ID: 22360156
[TBL] [Abstract][Full Text] [Related]
57. Is spastic muscle echo intensity related to the response to botulinum toxin type A in patients with stroke? A cohort study.
Picelli A; Bonetti P; Fontana C; Barausse M; Dambruoso F; Gajofatto F; Girardi P; Manca M; Gimigliano R; Smania N
Arch Phys Med Rehabil; 2012 Jul; 93(7):1253-8. PubMed ID: 22502807
[TBL] [Abstract][Full Text] [Related]
58. Purification and Characterization of Recombinant Botulinum Neurotoxin Serotype FA, Also Known as Serotype H.
Hackett G; Moore K; Burgin D; Hornby F; Gray B; Elliott M; Mir I; Beard M
Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29751611
[TBL] [Abstract][Full Text] [Related]
59. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
Park DI; Shin HM; Lee SY; Lew H
Acta Ophthalmol; 2013 Mar; 91(2):e108-12. PubMed ID: 23425111
[TBL] [Abstract][Full Text] [Related]
60. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves.
Black JD; Dolly JO
J Cell Biol; 1986 Aug; 103(2):521-34. PubMed ID: 3733877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
